Antipruritic Market to reach $14.3 Billion by 2031; The increasing prevalence of skin conditions, advancements in treatment options, growing awareness and diagnosis rates, rising demand for over-the-counter products

The Antipruritic Market size is estimated to reach $14.3 Billion by 2031, growing at a CAGR of 5.4% during the forecast period 2025-2031, according to a recent report published by IndustryARC, titled, “ Antipruritic Market - Antipruritic Market- By Drug (Corticosteroids, Counterirritants, Antihistamines, Topical Anesthetics , Immunomodulators and Others), By Route of Administration (Oral, Parenteral and Topical), By Application (Dermatitis, Insect Bites, Allergic Reactions and Others), By Distribution Channel (Offline and Online) and By Geography - Opportunity Analysis & Industry Forecast, 2025-2031.

The increasing prevalence of skin disorders, such as eczema, psoriasis and allergic reactions, is significantly driving the growth of the antipruritic market as more individuals seek effective treatments to manage their symptoms. Furthermore, the rising demand for over-the-counter (OTC) products, due to their accessibility and convenience, is further fueling the market's expansion, as consumers look for non-prescription options to alleviate itching and discomfort associated with various skin conditions.

In 2023, the North America region held the largest share of 38% driven by strong demand for innovative treatments and regulatory advancements in the United States. The U.S. market, in particular, is a key contributor to this growth. More than 16 million adults in the U.S. have eczema, and 6.6 million of these patients experience moderate-to-severe symptoms, according to the National Eczema Association. The FDA's rigorous approval process ensures that only safe and effective treatments reach the market, fostering consumer confidence in the therapies available. In September 2024, Eli Lilly and Company announced that the FDA approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 years and older, weighing at least 88 pounds (40 kg). The approval underscores the region's leadership in the development and regulatory approval of cutting-edge treatments for chronic skin conditions, further solidifying North America's position as a dominant player in the global antipruritic market. This trend is expected to continue, as advancements in dermatology and patient access to novel therapies drive market growth in the region.

 

Skin conditions, ranging from common issues like eczema and dermatitis to more complex diseases like prurigo nodularis and psoriasis, are becoming more widespread globally, creating a growing demand for effective treatments. The World Health Organization (WHO) reported in March 2023 that skin conditions affect an estimated 1.8 billion people at any given time. These conditions can have a profound impact on individuals' quality of life, leading to increased awareness and a higher demand for anti-pruritic treatments that can alleviate symptoms like itching and inflammation. In regions with limited resources, particularly in tropical settings, skin infections—which can be of bacterial, viral, fungal, or parasitic origin—are often the most common cause of disease. The WHO also noted that skin neglected tropical diseases (NTDs), such as scabies and leprosy, represent about 10% of skin diseases in these communities. This high prevalence of skin disorders, particularly in underserved areas, presents a clear opportunity for pharmaceutical companies to develop and provide more accessible and effective treatments for a growing global population.

As self-medication with non-prescription drugs becomes increasingly popular, the demand for over-the-counter (OTC) products continues to rise worldwide. According to a July 2023 article by AJMC, various factors beyond sunburns, such as plants, sweat, medications, sun sensitivity, and insect bites, are becoming significant concerns for many patients in the US. The American Skin Association reports that an estimated 50 million Americans are exposed to urushiol, the most common contact allergen, annually. Additionally, around 240 million Americans use over-the-counter (OTC) drugs each year, which are available without a prescription and can be safely used without the supervision of a healthcare provider. This growing trend reflects a shift in consumer behavior, where individuals are seeking accessible, convenient, and cost-effective solutions for managing common skin conditions like itching, eczema, and dermatitis, without the need for a prescription. This increasing self-medication practice is particularly relevant in the context of anti-pruritic products, as many people are looking for immediate relief from symptoms like itching and inflammation. OTC products, such as topical creams, lotions, and ointments, offer patients an easy and fast way to manage skin issues at home. As more consumers prioritize convenience and quick access to treatments, pharmaceutical companies are capitalizing on the demand by developing OTC products that provide effective relief for a variety of skin conditions.

Eli Lilly and Company, Galderma SA, Pfizer Inc., Amgen Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Johnson & Johnson, LEO Pharma, Incyte and others.

Rosacea Therapeutics Market - Rosacea Therapeutics Market size is estimated to reach $3.1 billion by 2027, growing at a CAGR of 6.7% during the forecast period 2022-2027, owing to the growing penetration of smartphones and  internet and the increasing predominance of rosacea in North America and Europe involving topical treatments is set to propel the market growth.

Atopic Dermatitis Treatment Market - The Atopic Dermatitis Treatment Market size is estimated to reach $24.8 billion by 2027 and poised to grow at a CAGR of 12.3% over the forecast period of 2022-2027, driven by the advancements in treatment options, growing awareness, expanding therapy pipelines, and rising recognition of the disease's social and emotional impact.

Multiple Sclerosis Drugs Market -Multiple Sclerosis Drugs Market size is estimated to reach $33660 Million by 2030, growing at a CAGR of 3.70% during the forecast period 2025-2031. The focus of firms on pipeline products for multiple sclerosis and the recommended continuous medicines for multiple sclerosis-like interferons to decrease the requirement for hospitalization due to COVID-19 are driving the growth.